Alpizarin tab 100mg 20 pieces

$9.42

Alpizarin tab 100mg 20 pieces

Quantity:

Description

Composition
Active substance:
1 tablet contains: Tetragidroksiglyukopiranozilksanten (Alpizarin®) (in terms of 100% substance) – 100 mg.
Excipients:
Milk sugar (lactose) – 0.1 g; krahmalkartofelny – 0.0475 g of calcium stearate (calcium stearate) -0.0025 g
Description:
Tablets round shape ploskotsilindricheskoy scored on one side and a facet on both sides of a light yellow color with a greenish hue or no color to yellow color with a greenish hue or no color with darker inclusions.
Product form:
Tablets of 100 mg.
10, 20, 30 tablets in blisters of PVC film and aluminum foil printed with termolakovym coating. 2 blisters № 10, or 1 contour cellular packaging № № 20 or 30 together with instructions for medical application is placed in a pile of cardboard for packaging consumer.
Contraindications
Increased sensitivity to the drug. Pregnancy.
Children up to age 3 years. Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Precautions: breastfeeding.
Dosage
100 mg
Indications
In the combined therapy of acute and recurrent infections caused by the herpes simplex virus of different localization (including genital); viral diseases of the oral mucosa (canker sores), herpes zoster, eczema herpeticum
Sarcoma, cytomegalovirus infection, chicken pox.
Interaction with other drugs
Not described.
Overdose
So far, cases of overdose have been reported. The emergence of an overdose is unlikely.
pharmachologic effect
Pharmacological group:
An antiviral agent.
Pharmacological properties:
Alpizarin® prepared from mangiferina emitted from the leaves of Indian Mango – Mangifera indica L., family sumach – Anacardiaceae.
Pharmacodynamics. Alpizarin® has antiviral activity against viruses: Herpes simplex type 1 and 2, Herpes zoster, Varicella zoster,
2 cytomegalovirus. The in vitro experiments shown tetragidroksiglyukopiranozilksantena inhibitory effect against human immunodeficiency virus.
Inhibitory dis tvie drug on the reproduction of the virus is particularly evident in the early stages of its development. Alpizarin® not affect the activity of the viral neuraminidase.
Alpizarin® has immunostimulating properties in respect of the cellular and humoral immunity, the ability to induce the production of interferon-gamma in blood cells.
Alpizarin® inhibits the growth of Gram-negative (Escherichia coli) and gram positive (Staphylococcus aureus, Mycobacterium tuberculosis) bacteria, fungi (Microsporum canis) and pathogenic protozoa (Entamoeba histolytica, Trichomonas vaginalis). The basis of the mechanism of action of the drug on the ability of suppressing bacterial nuclease activity.
Alpizarin® has a moderate anti-inflammatory action.
Pharmacokinetics:
Drug ingestion is rapidly absorbed from the gastrointestinal tract. The plasma unmodified tetragidroksiglyukopiranozilksanten determined for 0.5-5 hours after application.
Maximum concentration tetragidroksiglyukopiranozilksantena – 4.5 ug / ml reached after 1 hour after its application.
Tetragidroksiglyukopiranozilksanten largely bound to blood proteins (90-70%).
Dominated extrarenal elimination pathway tetragidroksiglyukopiranozilksantena.
The excretion of unchanged tetragidroksiglyukopiranozilksantena kidneys for 24 hours does not exceed 0.1%.
Pregnancy and breast-feeding
the allocation of data tetragidroksiglyukopiranozilksantena into breast milk is not, therefore, use of the drug during breastfeeding is possible only for health reasons, if the expected benefit to the mother outweighs the potential risk to the child. Should consult a doctor.
Conditions of supply of pharmacies
On prescription.
side effects
Allergic reactions.
special instructions
In the common case of lesions, and the presence of fever, lymphadenopathy and other common phenomena drug use “Alpizarin® 100 mg tablet” in combination with drug “Alpizarin® ointment for external topical use and 2% and 5%.”
1 tablet contains 0.1 g of milk sugar (lactose) and 0.0475 g of potato starch, which corresponds to 0.01 XE (bread units). The maximum daily dose for children aged 3 to 12 years comprising XE 0.03; for children over 12 years of age and adults – 0.08 BU.
The drug does not affect the performance of potentially hazardous activities or require high concentration and psychomotor speed reactions (transport management and working with moving machinery).
Storage conditions
In the dark place at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Tablets are used regardless of the meal. Adults and children over 12 years: 1-2 tablets 3-4 times a day for children 6-12 years – 1 tablet 2-3 times a day for children 3-6 years – 1 / 2-1 tablet 2- 3 times a day.
The therapeutic effect of the drug is most pronounced when it is implemented in the initial period of the disease. The duration of treatment depends on the type and severity of the disease:
– In case of frequent rashes acute and relapsing forms of genital herpes simplex like and Extragenital localization, and the presence of fever, lymphadenopathy and other common phenomena preparation is used for 5-14 days.
– When eczema herpetiformis sarcoma, and cytomegalovirus infection – for 7-21 days in the complex therapy.
– When aphthous stomatitis drug is prescribed for 5-15 days.
– In diseases caused by Herpes zoster (shingles) and Varicella zoster (chicken pox) – for 5-21 days.
When relapse repeat courses of drug treatment. To prevent a recurrence of herpesvirus infections the drug is prescribed in a month after treatment for 10-14 days.
The maximum daily dose for children aged 3 to 12 years of age is 300 mg (three tablets); for children over 12 years of age and adults – 800 mg (eight tablets).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

VILAR

There are no reviews yet.

Add your review